Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

Shots:

• This agreement will expand Mustang’s pipeline of ex vivo lentiviral gene therapies for the treatment of SCID
• Lentiviral gene therapy is currently being evaluated in a P-I/II clinical trial in the EU and has also received an ODD from the EMA for the RAG1-SCID program. The company plans to advance its therapy for RAG1-SCID to make it available for the patients 
• Mustang’s lead products, MB-107, and MB-207 are currently being evaluated for the treatment of XSCID & is expected to enroll its 1^st patient in a trial of MB-107 in Q1’22

Click here to­ read the full press release/ article | Ref: Globe Newswire | Image: Mustang Bio